BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weiss E, de la Grange P, Defaye M, Lozano JJ, Aguilar F, Hegde P, Jolly A, Moga L, Sukriti S, Agarwal B, Gurm H, Tanguy M, Poisson J, Clària J, Abback PS, Périanin A, Mehta G, Jalan R, Francoz C, Rautou PE, Lotersztajn S, Arroyo V, Durand F, Moreau R. Characterization of Blood Immune Cells in Patients With Decompensated Cirrhosis Including ACLF. Front Immunol 2020;11:619039. [PMID: 33613548 DOI: 10.3389/fimmu.2020.619039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hassan HM, Cai Q, Liang X, Xin J, Ren K, Jiang J, Shi D, Lu Y, Li T, Shang Y, He L, Chen X, Sun S, Li P, Guo B, Chen J, Yang H, Hu W, Chen X, Li J. Transcriptomics reveals immune-metabolism disorder in acute-on-chronic liver failure in rats. Life Sci Alliance 2022;5:e202101189. [PMID: 34853163 DOI: 10.26508/lsa.202101189] [Reference Citation Analysis]
2 Alabsawy E, Shalimar, Sheikh MF, Ballester MP, Acharya SK, Agarwal B, Jalan R. Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation. Aliment Pharmacol Ther 2022. [PMID: 35106777 DOI: 10.1111/apt.16790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Maini AA, Becares N, China L, Tittanegro TH, Patel A, De Maeyer RPH, Zakeri N, Long TV, Ly L, Gilroy DW, O'Brien A. Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway. JHEP Rep 2021;3:100332. [PMID: 34825153 DOI: 10.1016/j.jhepr.2021.100332] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Goel R, Eapen CE. Recognizing dysfunctional innate and adaptive immune responses contributing to liver damage in patients with cirrhosis. J Clin Exp Hepatol 2021. [PMID: 34744379 DOI: 10.1016/j.jceh.2021.10.001] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
6 Saha R, Pradhan SS, Shalimar, Das P, Mishra P, Singh R, Sivaramakrishnan V, Acharya P. Inflammatory signature in acute-on-chronic liver failure includes increased expression of granulocyte genes ELANE, MPO and CD177. Sci Rep 2021;11:18849. [PMID: 34552111 DOI: 10.1038/s41598-021-98086-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mallat A. EASL Recognition Award Recipient 2022: Dr Sophie Lotersztajn. J Hepatol 2022:S0168-8278(22)00322-1. [PMID: 35750546 DOI: 10.1016/j.jhep.2022.05.009] [Reference Citation Analysis]
8 Guo C, Dong C, Zhang J, Wang R, Wang Z, Zhou J, Wang W, Ji B, Ma B, Ge Y, Wang Z. An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients. Front Med (Lausanne) 2021;8:716869. [PMID: 34350203 DOI: 10.3389/fmed.2021.716869] [Reference Citation Analysis]
9 Liu S, Meng Q, Xu Y, Zhou J. Hepatorenal syndrome in acute-on-chronic liver failure with acute kidney injury: more questions requiring discussion. Gastroenterol Rep (Oxf) 2021;9:505-20. [PMID: 34925848 DOI: 10.1093/gastro/goab040] [Reference Citation Analysis]